320 related articles for article (PubMed ID: 25772240)
1. The role of Tcfap2c in tumorigenesis and cancer growth in an activated Neu model of mammary carcinogenesis.
Park JM; Wu T; Cyr AR; Woodfield GW; De Andrade JP; Spanheimer PM; Li T; Sugg SL; Lal G; Domann FE; Zhang W; Weigel RJ
Oncogene; 2015 Dec; 34(50):6105-14. PubMed ID: 25772240
[TBL] [Abstract][Full Text] [Related]
2. TFAP2C governs the luminal epithelial phenotype in mammary development and carcinogenesis.
Cyr AR; Kulak MV; Park JM; Bogachek MV; Spanheimer PM; Woodfield GW; White-Baer LS; O'Malley YQ; Sugg SL; Olivier AK; Zhang W; Domann FE; Weigel RJ
Oncogene; 2015 Jan; 34(4):436-44. PubMed ID: 24469049
[TBL] [Abstract][Full Text] [Related]
3. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis.
Cabodi S; Tinnirello A; Di Stefano P; Bisarò B; Ambrosino E; Castellano I; Sapino A; Arisio R; Cavallo F; Forni G; Glukhova M; Silengo L; Altruda F; Turco E; Tarone G; Defilippi P
Cancer Res; 2006 May; 66(9):4672-80. PubMed ID: 16651418
[TBL] [Abstract][Full Text] [Related]
4. Dual role of AP-2gamma in ErbB-2-induced mammary tumorigenesis.
Jäger R; Friedrichs N; Heim I; Büttner R; Schorle H
Breast Cancer Res Treat; 2005 Apr; 90(3):273-80. PubMed ID: 15830141
[TBL] [Abstract][Full Text] [Related]
5. Vitamin D receptor status alters mammary gland morphology and tumorigenesis in MMTV-neu mice.
Zinser GM; Welsh J
Carcinogenesis; 2004 Dec; 25(12):2361-72. PubMed ID: 15333467
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of miR-489 derails mammary hierarchy structure and inhibits HER2/neu-induced tumorigenesis.
Patel Y; Soni M; Awgulewitsch A; Kern MJ; Liu S; Shah N; Singh UP; Chen H
Oncogene; 2019 Jan; 38(3):445-453. PubMed ID: 30104710
[TBL] [Abstract][Full Text] [Related]
7. Targeting FACT complex suppresses mammary tumorigenesis in Her2/neu transgenic mice.
Koman IE; Commane M; Paszkiewicz G; Hoonjan B; Pal S; Safina A; Toshkov I; Purmal AA; Wang D; Liu S; Morrison C; Gudkov AV; Gurova KV
Cancer Prev Res (Phila); 2012 Aug; 5(8):1025-35. PubMed ID: 22689915
[TBL] [Abstract][Full Text] [Related]
8. Sustained trophism of the mammary gland is sufficient to accelerate and synchronize development of ErbB2/Neu-induced tumors.
Landis MD; Seachrist DD; Abdul-Karim FW; Keri RA
Oncogene; 2006 Jun; 25(23):3325-34. PubMed ID: 16434967
[TBL] [Abstract][Full Text] [Related]
9. EGFR Is Regulated by TFAP2C in Luminal Breast Cancer and Is a Target for Vandetanib.
De Andrade JP; Park JM; Gu VW; Woodfield GW; Kulak MV; Lorenzen AW; Wu VT; Van Dorin SE; Spanheimer PM; Weigel RJ
Mol Cancer Ther; 2016 Mar; 15(3):503-11. PubMed ID: 26832794
[TBL] [Abstract][Full Text] [Related]
10. Blockade of the epidermal growth factor receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu + MMTV/TGF-alpha bigenic mice.
Lenferink AE; Simpson JF; Shawver LK; Coffey RJ; Forbes JT; Arteaga CL
Proc Natl Acad Sci U S A; 2000 Aug; 97(17):9609-14. PubMed ID: 10931950
[TBL] [Abstract][Full Text] [Related]
11. USP22 overexpression fails to augment tumor formation in MMTV-ERBB2 mice but loss of function impacts MMTV promoter activity.
Kuang X; Salinger A; Benavides F; Muller WJ; Dent SYR; Koutelou E
PLoS One; 2024; 19(1):e0290837. PubMed ID: 38236941
[TBL] [Abstract][Full Text] [Related]
12. MMTV promoter hypomethylation is linked to spontaneous and MNU associated c-neu expression and mammary carcinogenesis in MMTV c-neu transgenic mice.
Zhou H; Chen WD; Qin X; Lee K; Liu L; Markowitz SD; Gerson SL
Oncogene; 2001 Sep; 20(42):6009-17. PubMed ID: 11593408
[TBL] [Abstract][Full Text] [Related]
13. Steroid receptor coactivator 1 deficiency increases MMTV-neu mediated tumor latency and differentiation specific gene expression, decreases metastasis, and inhibits response to PPAR ligands.
Han JS; Crowe DL
BMC Cancer; 2010 Nov; 10():629. PubMed ID: 21080969
[TBL] [Abstract][Full Text] [Related]
14. Dmp1α inhibits HER2/neu-induced mammary tumorigenesis.
Fry EA; Taneja P; Maglic D; Zhu S; Sui G; Inoue K
PLoS One; 2013; 8(10):e77870. PubMed ID: 24205004
[TBL] [Abstract][Full Text] [Related]
15. Identification of tumorsphere- and tumor-initiating cells in HER2/Neu-induced mammary tumors.
Liu JC; Deng T; Lehal RS; Kim J; Zacksenhaus E
Cancer Res; 2007 Sep; 67(18):8671-81. PubMed ID: 17875707
[TBL] [Abstract][Full Text] [Related]
16. Gene expression profiling of cancer progression reveals intrinsic regulation of transforming growth factor-beta signaling in ErbB2/Neu-induced tumors from transgenic mice.
Landis MD; Seachrist DD; Montañez-Wiscovich ME; Danielpour D; Keri RA
Oncogene; 2005 Aug; 24(33):5173-90. PubMed ID: 15897883
[TBL] [Abstract][Full Text] [Related]
17. The matrix metalloproteinase matrilysin influences early-stage mammary tumorigenesis.
Rudolph-Owen LA; Chan R; Muller WJ; Matrisian LM
Cancer Res; 1998 Dec; 58(23):5500-6. PubMed ID: 9850086
[TBL] [Abstract][Full Text] [Related]
18. A requirement for Nedd9 in luminal progenitor cells prior to mammary tumorigenesis in MMTV-HER2/ErbB2 mice.
Little JL; Serzhanova V; Izumchenko E; Egleston BL; Parise E; Klein-Szanto AJ; Loudon G; Shubina M; Seo S; Kurokawa M; Ochs MF; Golemis EA
Oncogene; 2014 Jan; 33(4):411-20. PubMed ID: 23318423
[TBL] [Abstract][Full Text] [Related]
19. Short-term early exposure to lapatinib confers lifelong protection from mammary tumor development in MMTV-erbB-2 transgenic mice.
Ma Z; Parris AB; Xiao Z; Howard EW; Kosanke SD; Feng X; Yang X
J Exp Clin Cancer Res; 2017 Jan; 36(1):6. PubMed ID: 28061785
[TBL] [Abstract][Full Text] [Related]
20. Vaccination with ErbB-2 peptides prevents cancer stem cell expansion and suppresses the development of spontaneous tumors in MMTV-PyMT transgenic mice.
Gil EY; Jo UH; Lee HJ; Kang J; Seo JH; Lee ES; Kim YH; Kim I; Phan-Lai V; Disis ML; Park KH
Breast Cancer Res Treat; 2014 Aug; 147(1):69-80. PubMed ID: 25104444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]